RSS0393
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
August 06, 2026
Efficacy and Safety of RSS0393 Ointment in Chronic Plaque Psoriasis: A Phase II Randomized Controlled Trial
(EADV 2026)
- No abstract available
Clinical • P2 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis
April 30, 2026
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=168 | Completed | Sponsor: Reistone Biopharma Company Limited | Active, not recruiting ➔ Completed
Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
April 22, 2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
(clinicaltrials.gov)
- P3 | N=600 | Not yet recruiting | Sponsor: Reistone Biopharma Company Limited
New P3 trial • Dermatology • Immunology • Psoriasis
January 30, 2026
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=168 | Active, not recruiting | Sponsor: Reistone Biopharma Company Limited | Recruiting ➔ Active, not recruiting
Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
July 23, 2025
A Randomized, Double-blind, Vehicle-controlled Phase I Study Evaluating the Safety and Pharmacokinetic Profile of RSS0393 Ointment as a Single and Multiple Dose Ascending Local Dermal Administration in Healthy and Adult Subjects with Psoriasis
(EADV 2025)
- P1 | "Local dermal administration of RSS0393 showed acceptable safety and tolerance of in healthy subjects and potential efficacy in psoriasis patients. These results support further clinical development of RSS0393 ointment for plaque psoriasis."
Clinical • P1 data • PK/PD data • Dermatology • Immunology • Psoriasis
September 23, 2025
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=168 | Recruiting | Sponsor: Reistone Biopharma Company Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
September 06, 2025
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=168 | Not yet recruiting | Sponsor: Reistone Biopharma Company Limited
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
August 06, 2025
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
(clinicaltrials.gov)
- P2 | N=20 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Dermatology • Immunology • Psoriasis
May 02, 2025
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
(clinicaltrials.gov)
- P1 | N=98 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2025
Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis
April 09, 2025
To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study
(clinicaltrials.gov)
- P2 | N=147 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Dermatology • Immunology • Psoriasis
March 13, 2024
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects
(clinicaltrials.gov)
- P1 | N=88 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Dermatology • Immunology • Psoriasis
1 to 11
Of
11
Go to page
1